Curing Multiple Sclerosis: How to Know When We're There

Overview

Journal Ann Neurol

Specialty Neurology

Date 2021 Jul 3

PMID 34216039

Citations 1

Authors

Stephen L Hauser

Affiliations

Soon will be listed here.

Citing Articles

Epstein-Barr virus sparks brain autoimmunity in multiple sclerosis.

Wekerle H Nature. 2022; 603(7900):230-232.

PMID: 35169323 DOI: 10.1038/d41586-022-00382-2.

References

Rudick R, Stuart W, Calabresi P, Confavreux C, Galetta S, Radue E . Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006; 354(9):911-23. DOI: 10.1056/NEJMoa044396. View

Mancuso R, Franciotta D, Rovaris M, Caputo D, Sala A, Hernis A . Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: a longitudinal study. Mult Scler. 2014; 20(14):1900-3. DOI: 10.1177/1352458514538111. View

Obermeier B, Mentele R, Malotka J, Kellermann J, Kumpfel T, Wekerle H . Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med. 2008; 14(6):688-93. DOI: 10.1038/nm1714. View

Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M . Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007; 130(Pt 4):1089-104. DOI: 10.1093/brain/awm038. View

Kappos L, Wolinsky J, Giovannoni G, Arnold D, Wang Q, Bernasconi C . Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol. 2020; 77(9):1132-1140. PMC: 7281382. DOI: 10.1001/jamaneurol.2020.1568. View

Schlaeger R, Papinutto N, Panara V, Bevan C, Lobach I, Bucci M . Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol. 2014; 76(4):568-80. PMC: 5316412. DOI: 10.1002/ana.24241. View

Lassmann H . Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis. Front Immunol. 2019; 9:3116. PMC: 6335289. DOI: 10.3389/fimmu.2018.03116. View

Cree B, Hollenbach J, Bove R, Kirkish G, Sacco S, Caverzasi E . Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol. 2019; 85(5):653-666. PMC: 6518998. DOI: 10.1002/ana.25463. View

Mattson D, Roos R, Arnason B . Isoelectric focusing of IgG eluted from multiple sclerosis and subacute sclerosing panencephalitis brains. Nature. 1980; 287(5780):335-7. DOI: 10.1038/287335a0. View

10.

Montalban X, Hauser S, Kappos L, Arnold D, Bar-Or A, Comi G . Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2016; 376(3):209-220. DOI: 10.1056/NEJMoa1606468. View

11.

Hauser S, Bar-Or A, Comi G, Giovannoni G, Hartung H, Hemmer B . Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2016; 376(3):221-234. DOI: 10.1056/NEJMoa1601277. View

12.

Hawker K, OConnor P, Freedman M, Calabresi P, Antel J, Simon J . Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009; 66(4):460-71. DOI: 10.1002/ana.21867. View

13.

Brandle S, Obermeier B, Senel M, Bruder J, Mentele R, Khademi M . Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins. Proc Natl Acad Sci U S A. 2016; 113(28):7864-9. PMC: 4948369. DOI: 10.1073/pnas.1522730113. View

14.

Mayssam E, Eid C, Khoury S, Hannoun S . "No evidence of disease activity": Is it an aspirational therapeutic goal in multiple sclerosis?. Mult Scler Relat Disord. 2020; 40:101935. DOI: 10.1016/j.msard.2020.101935. View

15.

Agius M, Klodowska-Duda G, Maciejowski M, Potemkowski A, Li J, Patra K . Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler. 2017; 25(2):235-245. PMC: 6360486. DOI: 10.1177/1352458517740641. View

16.

Absinta M, Vuolo L, Rao A, Nair G, Sati P, Cortese I . Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology. 2015; 85(1):18-28. PMC: 4501940. DOI: 10.1212/WNL.0000000000001587. View

17.

Larsson D, Akerfeldt T, Carlson K, Burman J . Intrathecal immunoglobulins and neurofilament light after autologous haematopoietic stem cell transplantation for multiple sclerosis. Mult Scler. 2019; 26(11):1351-1359. DOI: 10.1177/1352458519863983. View

18.

Elliott C, Wolinsky J, Hauser S, Kappos L, Barkhof F, Bernasconi C . Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Mult Scler. 2018; 25(14):1915-1925. PMC: 6876256. DOI: 10.1177/1352458518814117. View

19.

Wang J, Jelcic I, Muhlenbruch L, Haunerdinger V, Toussaint N, Zhao Y . HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple Sclerosis. Cell. 2020; 183(5):1264-1281.e20. PMC: 7707104. DOI: 10.1016/j.cell.2020.09.054. View

20.

Tourtellotte W, Murthy K, BRANDES D, Sajben N, Ma B, Comiso P . Schemes to eradicate the multiple sclerosis central nervous system immune reaction. Neurology. 1976; 26(6 PT 2):59-61. DOI: 10.1212/wnl.26.6_part_2.59. View